Effect of Oral Erythropoietin in neonatal with hypoxic ischemic encephalopathy

Effect of Oral Erythropoietin on tolerance of oral feeding, Prevention of Complications and reduction of mortality in neonatal with hypoxic ischemic encephalopathy

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140907019076N2

Enrollment

100

Registered

2021-06-19

Start date

2020-06-21

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic hypoxic encephalopathy. Hypoxic ischemic encephalopathy [HIE]

Interventions

Intervention 1: Intervention group: Erythropoietin is administered orally within the first 48 hours of birth dose 400 units per kg daily for 5 days (days 7, 5, 3, 1, 2) in addition to standard treatm

Eligibility

Sex/Gender

All

Age

1 Days to 30 Days

Inclusion criteria

Inclusion criteria: Gestational age more than and equal to 37 weeks prenatal asphyxia Grade 2 and 3 encephalopathy Conscious consent of parents

Exclusion criteria

Exclusion criteria: Birth weight <2200 g A genetic or congenital disease that affects nerve growth or requires multiple surgeries Head circumference <30 cm Polycythemia The infant should participate in another intervention period during hospitalization Asphyxia cases without HIE Metabolic diseases Confirmed infection

Design outcomes

Primary

Measure	Time frame
Effect of Oral Erythropoietin on tolerance of oral feeding, Prevention of Complications and reduction of mortality in neonatal with hypoxic ischemic encephalopathy. Timepoint: In the erythropoietin intervention group, orally within the first 48 hours of birth at a dose of 400 units per kilogram daily for 5 days (days 7,5,3,1,2). Method of measurement: By mouth or stomach catheter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeedeh Eshkil

Mashhad University of Medical Sciences

eshkils@mums.ac.ir+98 51 3852 1121

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026